3M inks three-way, $2.1B deal for drug unit

The conglomerate 3M says it has inked a trio of deals to sell its global branded drugs division for a collective $2.1 billion. Graceway Pharmaceuticals is buying the U.S., Canada and Latin American operation for $875 million while Sweden's Meda gets Europe for $857 million and two Australian equity firms gain Asia-Pacific for $349 million.

- here's the AP report on the deal

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.